Epoetin Alfa Increases Cardiovascular Risks When Targeting High Hemoglobin Levels, J&J Study Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.
You may also be interested in...
Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients
Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.
Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients
Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.
J&J Procrit Grows In Q1 Despite Challenges For ESAs
U.S. sales of the erythropoiesis-stimulating agent grew 1 percent in Q1 on strong sales in the hospital and retail market.